Skip to main content

Table 1 Health assessment questionnaire and short form-36 physical and mental component summary scores

From: Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

Instrument/

ETN + MTX

DMARD + MTX

P value

 Time on therapy

   

HAQ Score

Mean Score (% Improvement from Baseline) (N)

 

 Baseline

1.37 (0%) (N = 197)

1.41 (0%) (N = 103)

 

 Week 16

0.69 (49.4%) (N = 193)

0.87 (38.3%) (N = 100)

0.025*

HAQ Proportion

Patients achieving HAQ Score  ≤  0. 5, Proportion (%)

 

 Baseline

28/197 (14.2%)

13/103 (12.6%)

 

 Week 16

100/193 (51.8%)

39/100 (39.0%)

0.048**

SF-36 Physical Component Summary Scores

Mean Score (% Improvement from Baseline) (N)

 

 Baseline

30.5 (0%) (N = 193)

30.1 (0%) (N = 100)

 

 Week 16

40.4 (31.4%) (N = 189)

37.3 (22.8%) (N = 96)

0.003*

SF-36 Mental Component Summary Scores

Mean Score (% Improvement from Baseline) (N)

 

 Baseline

42.9 (0%) (N = 193)

42.4 (0%) (N = 100)

 

 Week 16

50.2 (17.5%) (N = 189)

47.8 (13.3%) (N = 96)

0.047*

  1. Scores at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN + MTX versus DMARD + MTX (Last Observation Carried Forward Analysis).
  2. DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy- Fatigue; HAQ: Health Assessment Questionnaire; MTX: methotrexate; SF-36: Medical Outcomes Short Form-36 Health Survey.
  3. Values have been rounded.
  4. *ANCOVA, considering the factors ‘baseline score + therapy + country’.
  5. **Cochran-Mantel-Haenszel Test.